Regulators clear AI devices fast, then lose sight of them. Approval was the easy part; the hard part starts the day the device meets real patients.
Health
Millions now talk to chatbots before therapists. The evidence says they help with access and first-step support, but fail exactly where care gets hard.
A court says ambient AI recordings are not medical records, even as vendors push AI deeper into clinical decisions.
Novartis lost $30 billion in market value when a late-stage trial missed. An AI start-up had predicted the failure months earlier using virtual patients.
Hospitals keep piloting AI because they buy tools instead of redesigning workflows. The fix is a safety test for the process, not the model.
Healthcare AI pilots impress, then stall at scale. The culprit is rarely the model. It is fragmented health data that no AI can safely learn from.
Doctors use AI as intended, patients get harmed, and the hospital still carries the blame. The liability standoff between health systems and AI vendors is now your problem.
AI now designs drug candidates in months, not years. But none are FDA-approved, so trust belongs in discovery, not in skipping human trials.
The patients who most need telehealth use it least. Broadband deserts and temporary Medicare rules keep the promise out of reach.
Your tracker counts everything, but a major review finds no significant change in clinical outcomes. Activity, not health, is what it moves.
Microsoft's AI beat doctors 83.2% to 36.1% on hard cases. But the tests were written puzzles, not real patients, and that gap is where your risk lives.